[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624834":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":21,"locations":30,"responsibleParty":54,"collaborators":21,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":21,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":21,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":77,"whyStopped":21,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ABBV-295 with Levonorgestrel and Ethinyl Estradiol","EXPERIMENTAL","Participants will receive subcutaneous doses of ABBV-295 with levonorgestrel and ethinyl estradiol for 68 days.",[13,14],"Drug: ABBV-295","Drug: Levonorgestrel\u002FEthinyl Estradiol",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","ABBV-295","Subcutaneous Injections",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Levonorgestrel\u002FEthinyl Estradiol","Oral Tablet",[9],[27],{"name":28,"affiliation":5,"role":29},"ABBVIE INC.","STUDY_DIRECTOR",[31,44],{"facility":32,"status":21,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":21},"CenExel ACT- Anaheim Clinical Trials \u002FID# 281863","Anaheim","California","92801","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-117.9145,33.83529,{"lat":42,"lon":41},{"facility":45,"status":21,"city":46,"state":47,"zip":48,"country":36,"countryCode":37,"cosmosGeoPoint":49,"geoPoint":53,"contacts":21},"Acpru \u002FId# 280538","Grayslake","Illinois","60030",{"type":39,"coordinates":50},[51,52],-88.04175,42.34447,{"lat":52,"lon":51},{"type":55,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100624834","phase-1-a-study-of-abbv-295-subcutaneous-injections-to-assess-pharmacokinetics-and-adverse-events-in-healthy-adult-women-participants-with-overweight-or-obesity-taking-oral-contraceptives-100624834",false,"NCT07414784","A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives","A Phase 1 Drug-Drug Interaction Study of ABBV-295, Levonorgestrel, and Ethinyl Estradiol in Healthy Adult Female Subjects With Overweight or Obesity","Inclusion Criteria:\n\n* BMI ≥ 25.0 to ≤ 35.0 kg\u002Fm2 after rounding to the tenths decimal at Screening (BMI is calculated as weight in kg divided by the square of height measured in meters)\n* A female who is not pregnant or breastfeeding and is not considering becoming pregnant or donating eggs during the study or for approximately 60 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Participant has a self-reported change in body weight ≥ 5% within 3 months prior to Screening.\n* HbA1c ≥ 6.5% and\u002For serum glucose ≥ 126 mg\u002FdL at Screening.\n* Participant has taken a medication for the purpose of treating obesity or has been enrolled in an obesity trial within 90 days prior to study treatment administration.",true,"FEMALE","18 Years","65 Years",{"count":68,"type":69},20,"ACTUAL","INTERVENTIONAL",[72],"PHASE1","This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.",[75],"Healthy Volunteer",[75,18],"ACTIVE_NOT_RECRUITING","2026-04-24",{"date":80,"type":69},"2026-04-27",{"date":82,"type":69},"2026-02-11",{"date":84,"type":85},"2026-07","ESTIMATED",{"name":5,"class":6},2]